Who are Nilotinib 300 mg.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): imatinib (IM), DW6012(Dasidiem tab. 10/100mg), Dasatinib Tablets, Mercaptopurine, Imatinib, Chemotherapy + Imatinib, treatment of TKI in CML.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nilotinib-300-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nilotinib 300 mg. — Competitive Intelligence Brief

Nilotinib 300 mg. (Nilotinib 300 mg.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BCR-ABL tyrosine kinase inhibitor. Area: Oncology.

marketed BCR-ABL tyrosine kinase inhibitor BCR-ABL Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Nilotinib 300 mg. (Nilotinib 300 mg.) — King Abdullah International Medical Research Center. Nilotinib is a tyrosine kinase inhibitor that selectively blocks BCR-ABL and other kinases to inhibit abnormal cell proliferation in chronic myeloid leukemia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nilotinib 300 mg. TARGET	Nilotinib 300 mg.	King Abdullah International Medical Research Center	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL
imatinib (IM)	imatinib (IM)	First Affiliated Hospital, Sun Yat-Sen University	marketed	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
DW6012(Dasidiem tab. 10/100mg)	DW6012(Dasidiem tab. 10/100mg)	Dong Wha Pharmaceutical Co. Ltd.	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases
Dasatinib Tablets	Dasatinib Tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL, SRC family kinases
Mercaptopurine, Imatinib	Mercaptopurine, Imatinib	St. Jude Children's Research Hospital	phase 3	Purine analog antimetabolite and tyrosine kinase inhibitor combination	Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib)
Chemotherapy + Imatinib	Chemotherapy + Imatinib	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Tyrosine kinase inhibitor + chemotherapy combination	BCR-ABL, c-KIT, PDGFR
treatment of TKI in CML	treatment of TKI in CML	Poitiers University Hospital	phase 3	Tyrosine kinase inhibitor	BCR-ABL

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BCR-ABL tyrosine kinase inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Il-Yang Pharm. Co., Ltd. · 1 drug in this class
King Abdullah International Medical Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nilotinib 300 mg. — Competitive Intelligence Brief. https://druglandscape.com/ci/nilotinib-300-mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab